Compare Global E Online Ltd (GLBE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs TG Therapeutics Inc — how do they compare? Global E Online Ltd trades at $40.37 (market cap $6.75B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is more actively traded (1,735,121 versus 1,468,708). Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and TG Therapeutics Inc for 16 Days on average.
| GLBE | TGTX | |
|---|---|---|
Market Cap | $6.75B | $8.16B |
Volume | 1,468,708 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $59.06 |
52-Week Low | $27.54 | $26.94 |
Typical Hold Time | 21 Days | 16 Days |
Enterprise Value | $6.24B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $40.25, up 3.31% today, with a bullish technical signal from moving averages and strong analyst consensus. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth of 39% year-over-year. Recent news includes the appointment of a new Chief Revenue Officer and significant insider selling by executives.
The outlook is positive, supported by strong revenue growth, expanding margins, and a high analyst buy rating. Key risks include elevated valuation multiples, insider selling pressure, and dependence on e-commerce market conditions. The stock offers potential upside to the consensus price target of $48.86.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
